• Like

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

4 nov 2010: Presentation Roland Lageveen on biotechnology in the NL.

  • 803 views
Uploaded on

Biofarmind celebrates its 12.5th anniversary. Roland Lageveen (IQ Corporations) talks about biotechnology in the Netherlands.

Biofarmind celebrates its 12.5th anniversary. Roland Lageveen (IQ Corporations) talks about biotechnology in the Netherlands.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
803
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
9
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • Our approach is paying offIn 2008 a strong growth in attracted venture capital against all oddsIn the top 10 European biotech-Pharma partnerships, 5 involve Dutch SME’sAn example: Prosensaand its partnership with GSK - Development and commercialization of RNA based therapeutics for Duchenne Muscular Dystrophy (DMD)- Deal value of upfront and milestone payments USD 655 million

Transcript

  • 1. LìfeSciencesHealth, a shiningfuture?
    Dr. Roland Lageveen
    CEO IQ Corporation
    Biotechnology in the Netherlands
  • 2. The Dutch life sciences and health innovation cluster (LSH) builds upon a strong knowledge base
    Strong national cluster: First rate academia, hundreds of SME’s, multinational med- & biotech and Pharma, all within a 120 mile radius
    Focal points around:- Amsterdam/Leiden/Rotterdam/Utrecht- Groningen- Wageningen/Nijmegen - Eindhoven/Maastricht
    World class:
    Two Dutch clusters are in the global Top 40 and the European Top 15 for biotech patent applications.
    120 mile radius
    Excellent biobanks and ‘real life’ data
    infrastructure
    Global players & very high concentration of SMEs
  • 3. …with excellent output levels 2,5% of world science output
    www.worldmapper.org
    • Impact publications number 4
    • 4. Publication productivity number 2
    • 5. Patent productivity number 1
  • Source: OECD, Biotechnology Statistics 2009
    …and a good biotechnology patent productivity too…
    patent productivity number 1
  • 6. Health-related life sciences: an important sector in the Dutch economy
    Drugs
    – 430 companies; EUR 12 bn revenues; 37,000 FTE
    Diagnostics
    – 390 companies; EUR 2.7 bn revenues; 12,000 FTE
    Biomedical Engineering and Devices
    – 75 companies; EUR 0.4 bn revenues; 2,200 employees
    Other
    –40 companies,  EUR 0.8 bn revenues
    Health-related life sciences: 935 companies – 150 highly innovative; EUR 15.9 bn output (3% of GDP); 54,600 FTE
    Source: EIM study for EZ [2006], Voorstel LSG [2006]
  • 7. 5 of the top 10 European biotech deals are with Dutch companies, with a total valueexceeding USD 2 billion
  • 8. However….
  • 9. …but a low performance on innovation & entrepreneurship and applications
    Intellectual
    Property
    Innovation
    drivers
    Knowledge
    creation
    Innovation &
    Entrepreneurship
    Applications
    Source: European Innovation Scoreboard 2006
  • 10. After UK, the Netherlands has 2nd lowestmarketuptake of innovative medicines
  • 11. NyenrodeBiotech Outlook: The performance of Dutch cluster is low butimproving
  • 12. Investments in PPPs are huge, but will decline
    PPP programs – duration and total investment
    Investment in time [EUR m] (committed 2003-2007)
    ??
    11
    10
    09
    08
    15
    07
    06
    14
    13
    12
    Program
    [EUR m]
    FES 2009
    NGI
    5001)
    Committed
    Taken to the next level…
    TI Pharma
    240
    CTMM
    400
    90
    BMM
    dpte
    50
    25
    TERM
    24
    NIMIC
    182
    …or…
    24
    Braingain
    28
    Arthrosite
    23
    TREND
    …momentum lost?
    7
    BioMaDe
    Neuro-BSIK
    26
    Mol Im Heart
    20
    42
    SCDD
    18
    34
    Cyttron
    18
    11
    0
    0
    Parelsnoer
    67
    LifeLines
    5
    2007
    2008
    2009
    2010
    2011
    2012
    2013
    2014
    2015
    1) Includes also non-health related investments
    Source: PPP websites; Senternovem; Ministery of Economic Affairs
    11
  • 13. The government recognizes life sciences as ‘topgebied’, next to food & flowers and chemicals
  • 14. The government recognizes life sciences but their budgets ......
    Wbso higher
    Tax lower
    But:
    No specific programs
    No FES funding
    No vision
  • 15. The international environment is changing…..
  • 16. 15
    The big Pharma challenge: R&D expenditure goes up, output in new medicines goes down
    R&D investments [USD billions] versus output [approved new medicines]
    Development of a new drug has become more complex: safety & efficacy are the two main issues
    Costs to develop one new drug have become approximately EUR 1 billion
    FDA approved new medicines
    R&D investments
    FDA approved new medicines [#]
    R&D investment [USD billion]
    Source: PhRMA, FDA
  • 17. Reducingcostsandfillingpipelines are twomain drivers for consolidation in big Pharma
    Examples of mergers and acquisitions in big Pharma
  • 18. ...with a major impact on the Netherlands
    Organon
    Solvay
    Crucell
  • 19. At the same time big Pharma triestofillitspipelinesbyincreasingexternal R&D activities
    Examplesfromthree major Pharma companieswithhighlights of their R&D strategy
    Source: annual reports and websites GSK, Merck, and AstraZeneca, and Morgan Stanley report on AZ
  • 20. The changing environment holds opportunities for the Netherlands….
  • 21. Societal, technological and stakeholder trends holds opportunities for the Netherlands
    1
    Societal trends
    Increased burden on the healthcare system
    • Ageing
    • 22. Unhealthy lifestyle
    • 23. Demand for high quality of life
    2
    Technological trends
    26%
    24%
    % population >65 years in the Netherlands
    20%
    New technologies promise:
    • Early diagnosis
    • 24. Targeted delivery of drugs
    • 25. Personalized medicine
    15%
    2010
    2020
    2030
    2040
    3
    Stakeholder trends
    Bio-artificial kidney
    4
    Dutch business environment and government innovation policy
    • Promising business environment
    • 28. Life sciences anchored on short term in government innovation policy
    • 29. Pitfall is lack of continuity in policy
  • The Netherlands has a good start position to turn into an international breeding ground for new businesses
    Increasing demand for innovations
    Increasing specialization
    Strong Dutch knowledge base
    Highly educated people
    Strong innovation infrastructure
    Growing industry
    Internationally competitive breeding ground for new business in life sciences and health
    +
    +
    +
    +
    +
    =
    OPPORTUNITY TO BECOME
  • 30. How can we grab the opportunities ?
  • 31. A clear challenge for the Dutch sector: big and small, clinical and pre-clinical, public and private, branch organizations now have to join forces
  • 32. Generation
    Translation
    Delivery
    A healthy pipeline…
    …acting as a well oiled engine…
    …delivering continuously…
    …with a technology push…
    …with a strong industry pull
    BUILD
    BENEFIT
    BUNDLE
    …resting on a strong knowledge base…
    Creating a healthy pipeline by building true partnerships
  • 33. Invest on an annual basis with a stable budget for a longer period instead of incidental impulse financing
    The sector should take responsibility for a long term strategy
    Taken to the next level…
    182
    …or…
    …momentum lost?
    42
    34
    11
    0
    0
    2007
    2008
    2009
    2010
    2011
    2012
    2013
    2014
    2015
  • 34. Improve the LSH climate
    Creating a SME friendly environment fostered by a government with long term vision and a positive LSH attitude
    Remove regulation hurdles
    Focus on value creation in the reimbursement evaluation procedure
    Increase the availability of human resources
    Improve entrepreneurial skills
    Make EC’s “Innovation Union” work for us, in funding R&D and matching VC
    Market the Netherlands internationally as one unique life sciences region
  • 35. Keep effective, successful instruments up and running
    For example: ‘Innovatiekrediet’
    1 euro credit loan…
    generates 2 euro private investment
    +
    2009: 13 mln. + 26 mln. = 39 mln.
  • 36. Stakeholders should team up to realize these goals
    The knowledge base: UMC’s and Universities
    The industry: small and large
    The financing world
    The branch organizations
    Patient organizations
    Health care providers
    Health insurers
    ….
  • 37. One voice one message …. ….. show our successes!
    Dutch Masters in Life Sciences Health,
    …..The Dutch Innovation
  • 38. Biotechnology in the NetherlandsLSH a shiningfuture?Let’s team up to makeit happen together
    Dr. Roland Lageveen
    CEO IQ Corporation